NYSEAMERICAN:OCXOncoCyte Stock Price, Forecast & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for OncoCyte.

OncoCyte is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for OncoCyte.

OncoCyte Corp (NYSEAMERICAN:OCX) posted its quarterly earnings data on Wednesday, July, 29th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.03. The biotechnology company earned $0.14 million during the quarter, compared to the consensus estimate of $0.04 million.
View OncoCyte's earnings history.

5 brokers have issued 1 year price targets for OncoCyte's stock. Their forecasts range from $2.00 to $7.50. On average, they anticipate OncoCyte's share price to reach $4.70 in the next twelve months. This suggests a possible upside of 174.9% from the stock's current price.
View analysts' price targets for OncoCyte.

News articles about OCX stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OncoCyte earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about OncoCyte.

OncoCyte saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,870,000 shares, an increase of 52.0% from the June 15th total of 1,230,000 shares. Based on an average trading volume of 702,600 shares, the short-interest ratio is currently 2.7 days.
View OncoCyte's Short Interest.

Some companies that are related to OncoCyte include Neptune Wellness Solutions (NEPT), IMV (IMV), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Verona Pharma (VRP), Synairgen (SNG), Ibio (IBIO), ProMetic Life Sciences (PLI), Fennec Pharmaceuticals (FRX), Ergomed (ERGO), Rafael (RFL), IMV (IMV), Tiziana Life Sciences (TILS) and Medicenna Therapeutics (MDNA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), BioTime (BTX), Fulcrum Therapeutics (FULC), Alnylam Pharmaceuticals (ALNY), VIVUS (VVUS), Aldeyra Therapeutics (ALDX), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), SCYNEXIS (SCYX) and AcelRx Pharmaceuticals (ACRX).

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Phoenix Holdings Ltd. (0.43%), EAM Investors LLC (0.36%), P.A.W. Capital Corp (0.30%), Private Wealth Partners LLC (0.22%), Bank of New York Mellon Corp (0.17%) and New York State Common Retirement Fund (0.06%). Company insiders that own OncoCyte stock include Albert P Parker, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp.
View insider buying and selling activity for OncoCyte.

OCX stock was acquired by a variety of institutional investors in the last quarter, including EAM Investors LLC, Private Wealth Partners LLC, Bank of New York Mellon Corp, New York State Common Retirement Fund, Phoenix Holdings Ltd., Virtu Financial LLC, American International Group Inc., and Goldman Sachs Group Inc.. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OCX stock can currently be purchased for approximately $1.71.

OncoCyte has a market capitalization of $115.00 million. OncoCyte employs 12 workers across the globe.

The official website for OncoCyte is www.oncocyte.com.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.